Sophie Peigné, Ph.D.

Senior Director, MIDD Consultant

Portrait-of-Sophie-Peigne-Pharmetheus-1

Bio

  • Joined Pharmetheus in 2022, actively working in client projects
  • Expertise includes clinical pharmacokinetics, pediatric drug development, in-vitro in-vivo correlation, and pharmacometrics in therapeutic areas such as oncology, immuno-oncology, cardiology, and neurology
  • Previously worked as PK Project Manager and Principal Pharmacometrician at Servier, France
  • Pharm.D. (2010), Master Degree in Pharmacokinetics (2010), and Ph.D. in Pharmacometrics (2015) from the University of Paris V, France
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Direct and hybrid machine learning approaches do not outperform NLME-based full Bayesian forecasting for early identification of delayed methotrexate eliminationExposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancerPopulation pharmacokinetic analysis of Datopotamab deruxtecan (Dato-DXd), a TROP2-targeting antibody-drug conjugate